Bandello, F;
Querques, G;
Loewenstein, A;
Özdek, Ş;
Rezai, K;
Laurent, K;
Bilgic, A;
... Kuppermann, BD; + view all
(2023)
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey).
Expert Opinion on Biological Therapy
, 23
(8)
pp. 851-859.
10.1080/14712598.2023.2176218.
Preview |
Text
Submitted PDF.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Purpose: To assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe. // Methods: A 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan 31, 2022. A total of 112 respondents (retinal physicians) from the US and Europe participated. // Results: The majority of the physicians (56.3%) were familiar with anti-VEGF biosimilars. A significant number of physicians needed more information (18.75%) and real world data (25%) before switching to a biosimilar. About one half of the physicians were concerned about biosimilar safety (50%), efficacy (58.9 %), immunogenicity (50%), and their efficacy with extrapolated indications (67.8 %). Retinal physicians from the US were less inclined to shift from off-label bevacizumab to biosimilar ranibizumab or on-label bevacizumab (if approved) compared to physicians from Europe (p=0.0001). Furthermore, physicians from the US were more concerned about biosimilar safety (p=0.0371) and efficacy compared to Europe (p= 0.0078). // Conclusions: The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.
| Type: | Article |
|---|---|
| Title: | Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey) |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/14712598.2023.2176218 |
| Publisher version: | http://dx.doi.org/10.1080/14712598.2023.2176218 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Bio-USER; survey; awareness; Anti-VEGF; retina; biosimilar; ophthalmology; United States; europe |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10197955 |
Archive Staff Only
 |
View Item |
